Dextran Products Wins Awards for Water Conservation Efforts

Toronto, Dec. 10, 2018 (Globe Newswire) -- Polydex Pharmaceuticals Limited (OTC MKTS:POLXF) (the “Company”) operating as Dextran Products, today announced it has received two awards for water conservation efforts.

For several years, Management has been focusing on maintaining profitability while improving production efficiencies in order to meet worldwide demand for the company’s signature core dextran products.

Recently it became clear to George Usher, CEO and President of Polydex Pharmaceuticals, that cost savings could be achieved through water conservation. “We go through about 105 million litres of water per year,” Mr. Usher explained “and I had been hearing of a growing trend to conserve water and hence utility costs in the process. Ultimately in collaboration with Partners in Project Green https://www.partnersinprojectgreen.com/ and Enviro Stewards https://www.enviro-stewards.com, we started investigating systems to re-direct water, with the goal of reducing costs in the process. Initially the intent was simply to save money; however we are now enjoying the process of going green as an added benefit.”

The Company has recently been honored with two Awards for its achievements and visionary efforts. https://clean50.com/project/dextran-enviro-stewards-inc-saving-water-energy

Mr. Usher continued, “Over the course of the past year, we made major improvements to the production equipment, including a new boiler, re-tubing of the existing boiler and several other modifications as part of our investment into the future. As a result we are hoping for important savings in utility costs, although these are difficult to quantify at present. Receiving awards for those efforts is an unexpected and encouraging benefit.”

The Company’s publicly traded shares continue to be quoted on the OTC Pink Sheet platform (www.otcmarkets.com/stock/POLXF/quote).

The Company continues full disclosure of its financial and operational results, which can be accessed by visiting the company website at www.Polydex.com.  Information about the Company’s products is available at www.dextran.ca

Polydex Pharmaceuticals Limited, based in Toronto, Ontario, Canada, is engaged in the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry and also the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. Company website: www.Polydex.com

Contact:

Investor Relations: North Arm Capital Services, Linda Hughes, 1-877-945-1621 (PolydexIR@gmail.com)

All Topics